Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2003
10/16/2003US20030195198 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
10/16/2003US20030195196 Pyrrolobenzodiazepines
10/16/2003US20030195194 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/16/2003US20030195189 For therapy of hyperproliferative diseases
10/16/2003US20030195181 Laulimalide derivatives
10/16/2003US20030195179 Redispersibility comprising polyvinylpyrrolidone and a water-soluble anionic macromolecular compound which are added to prevent a hardly soluble drug from adhering to a container and forming aggregates
10/16/2003US20030195173 Colchinol derivatives as angiogenesis inhibitors
10/16/2003US20030195171 Method for inhibiting bone resorption with an alendronate and vitamin D formulation
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195164 Novel ribozyme and its use
10/16/2003US20030195156 Tumor necrosis factors; cytokines; immunoglobulins; autoimmune diseases
10/16/2003US20030195153 Comprises metalloproteinase (stromelysin) inhibitors
10/16/2003US20030195152 Polymeric conjugates of antitumor agents
10/16/2003US20030194804 For enhancing T cell response to tumour cells
10/16/2003US20030194802 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
10/16/2003US20030194787 Fermentative preparation process for and crystal forms of cytostatics
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194739 Using cancer specific genes
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194725 Creating a database of related protein/nucleic acid sequences with annotations of the potential disease associations of the sequences; testing the potential disease associations by means of a biological assay and validating the disease association
10/16/2003US20030194720 Human ion channels
10/16/2003US20030194406 P-cadherin as a target for anti-cancer therapy
10/16/2003US20030194400 Targeted thrombosis
10/16/2003US20030194398 Having serine protease inhibitory activity
10/16/2003US20030194390 Alkyl cyanoacrylate and inhibitor and aggregate structure formed; alkyl fatty ester, opacifier; ablating tissue by blocking blood flow
10/16/2003US20030194389 Occlusive composition
10/16/2003US20030194375 Anti-epileptogenic agents
10/16/2003US20030192226 Animal decoy
10/16/2003CA2513149A1 A human ribonucleotide reductase m2 subunit
10/16/2003CA2482253A1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2481925A1 Therapeutic agent for patients having human fc.gamma.riiia
10/16/2003CA2481920A1 Antibody composition-containing medicament
10/16/2003CA2481888A1 Alpha, omega-dicarboximide derivatives as useful uro-selective a1a adrenoceptor blockers
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481837A1 Production process for antibody composition
10/16/2003CA2481829A1 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/16/2003CA2481719A1 Modified cea nucleic acid and expression vectors
10/16/2003CA2481658A1 Method of enhancing of binding activity of antibody composition to fcy receptor iiia
10/16/2003CA2481657A1 Cells of which genome is modified
10/16/2003CA2481656A1 Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
10/16/2003CA2481466A1 Depsipeptide for therapy of kidney cancer
10/16/2003CA2481392A1 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003CA2481090A1 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2481026A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480709A1 Method of improving absorption of vitamin e by a pet animal
10/16/2003CA2480579A1 Embolization
10/16/2003CA2480446A1 Method and dietary composition for improving lipid digestibility
10/16/2003CA2480311A1 Oligomeric compounds for the modulation of hif-1alpha expression
10/16/2003CA2479810A1 Polymeric acyl derivatives of indoles
10/16/2003CA2477943A1 Heterocyclic amides with alpha-4 integrin antagonist activity
10/16/2003CA2477935A1 Multivalent constructs for therapeutic and diagnostic applications
10/16/2003CA2477298A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/16/2003CA2453020A1 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases
10/15/2003EP1352970A1 Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabloized per se by ugt1a1 or whose intermediate is metabolized by the enzyme
10/15/2003EP1352956A1 Inhibition of DNA methyltransferase
10/15/2003EP1352955A2 HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula
10/15/2003EP1352897A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352896A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352895A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352662A1 Conjugates of an antibody and a water-soluble polymer used in immunoliposomes
10/15/2003EP1352657A1 Interferon therapeutic effect-potentiating agents
10/15/2003EP1352088A2 Genes comprising coding mononucleotide microsatellites or dinucleotide microsatellites that can be isolated from tumor cells
10/15/2003EP1352063A2 Receptor nucleic acids and polypeptides
10/15/2003EP1352062A2 Improved growth hormone molecules
10/15/2003EP1352061A2 Method for inhibiting the expression of a target gene
10/15/2003EP1352056A2 Polypeptides
10/15/2003EP1352054A2 Aspergillus ochraceus 11 alpha hydrolase and oxidoreductase
10/15/2003EP1352053A2 Method for processing dendritic cells and for activating macrophages with ru 41740
10/15/2003EP1352052A1 Ancillary composition for the preparation of committed mature dentritic cells
10/15/2003EP1352051A2 In vivo animal model of human leukemia
10/15/2003EP1351985A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
10/15/2003EP1351980A2 Peptides for activation and inhibition of delta pkc
10/15/2003EP1351969A1 Method for generating immortal dendritic cell lines
10/15/2003EP1351967A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/15/2003EP1351966A1 Improved specificity in treatment of diseases
10/15/2003EP1351962A2 Thienopyrimidine
10/15/2003EP1351958A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
10/15/2003EP1351957A1 Chemical derivatives and their use as anti-telomerase agent
10/15/2003EP1351956A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
10/15/2003EP1351954A1 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
10/15/2003EP1351946A2 Materials and methods to potentiate cancer treatment
10/15/2003EP1351941A1 Bisaryl derivatives having fsh receptor modulatory activity
10/15/2003EP1351938A1 Phenyl derivatives
10/15/2003EP1351934A1 Naphthalene derivatives which bind to the ep4 receptor
10/15/2003EP1351930A2 Protease inhibitors
10/15/2003EP1351926A2 Novel bifunctional chelating compounds containing hydroxamic acid residues
10/15/2003EP1351924A2 Diamines as modulators of chemokine receptor activity
10/15/2003EP1351916A2 Ether compounds and compositions for cholesterol management and related uses
10/15/2003EP1351912A2 Substituted stilbenes, their reactions and anticancer activity
10/15/2003EP1351712A2 Targeted combination immunotherapy of cancer and infectious diseases
10/15/2003EP1351709A2 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
10/15/2003EP1351708A1 Therapeutic agent comprising a b-subunit of a protein toxin
10/15/2003EP1351694A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/15/2003EP1351691A1 Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
10/15/2003EP1351686A2 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
10/15/2003EP1351678A2 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
10/15/2003EP1351677A2 Method for treating cancer
1 ... 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 ... 2211